Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.005x
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a cash flow conversion efficiency ratio of 0.005x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.57 Million) by net assets (CN¥2.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Whirlpool of India Limited
NSE:WHIRLPOOL
|
0.143x |
|
Gedik Yatirim Menkul Degerler AS
IS:GEDIK
|
-0.435x |
|
Baotou Dongbao Bio-Tech Co Ltd
SHE:300239
|
0.005x |
|
PHARMANUTRA S.P.A.
F:761
|
N/A |
|
Danal Co. Ltd
KQ:064260
|
-0.042x |
|
Cinda Real Estate Co Ltd
SHG:600657
|
-0.002x |
|
Holtek Semiconductor Inc
TW:6202
|
0.034x |
|
Jiangsu Boamax Technologies Group Co Ltd
SHE:002514
|
0.095x |
Annual Cash Flow Conversion Efficiency for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.31 Billion | CN¥96.07 Million | 0.042x | -28.48% |
| 2023-12-31 | CN¥2.36 Billion | CN¥137.06 Million | 0.058x | -47.21% |
| 2022-12-31 | CN¥2.28 Billion | CN¥250.79 Million | 0.110x | +97.51% |
| 2021-12-31 | CN¥2.22 Billion | CN¥123.98 Million | 0.056x | -67.89% |
| 2020-12-31 | CN¥700.39 Million | CN¥121.67 Million | 0.174x | -77.22% |
| 2019-12-31 | CN¥488.25 Million | CN¥372.33 Million | 0.763x | +300.27% |
| 2018-12-31 | CN¥399.87 Million | CN¥76.18 Million | 0.191x | +189.57% |
| 2017-12-31 | CN¥307.65 Million | CN¥-65.44 Million | -0.213x | -- |